Skip to main content
. Author manuscript; available in PMC: 2019 Aug 23.
Published in final edited form as: Bioconjug Chem. 2019 Jul 5;30(7):2049–2059. doi: 10.1021/acs.bioconjchem.9b00332

Figure 5.

Figure 5.

GAD541–554BC with or without F4/80 Ab ex vivo and in vivo study. (A) Ex vivo evaluation of GAD541–554BC with or without F4/80 Ab on prediabetic NOD mouse splenocytes using CFSE treated proliferation assay. (B) Ex vivo study of GAD541–554BC on prediabetic mouse splenocytes using IFNγ ELISPOT assay. (C) in vivo study of GAD541–554BC with or without F4/80 Ab in NOD mice. Six week old NOD mice were treated with GAD541–554BC with or without F4/80 Ab for three consecutive weeks and evaluated for IFNγ secreting cells in treated mouse spleen at the end of 12 weeks of age. One way ANOVA followed by Tukey’s multiple comparison test was used: n = 3, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.